With an eye to 'non-obvious binding sites,' CBC Group launches precision medicine play with $67M and ex-Editas exec at the helm
Over the past year, CBC Group has been quietly incubating a biotech to take advantage of the AI rush and make some new therapies against hard-to-drug oncology targets. And it’s now enticed a tech investor to pick up the tab on the Series A.
ENSEM Therapeutics is launching with $67 million from GGV Capital — which has backed companies like Airbnb, Alibaba and Slack — and Pavilion Capital, Cenova Capital, Mitsui & Co. Global Investment and CBC Group.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.